药物诱导的血小板功能障碍可以逆转吗?
Suzanne Maynard1,2,3, Alexander P Bye4, Michael J R Desborough1,2,3
1Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.
Research and practice in thrombosis and haemostasis
|January 16, 2026
概括
逆转抗血小板药物可能会降低严重疾病患者的出血风险. 然而,当前的逆转策略,如血小板输血和松酸有局限性,需要进一步研究有效的治疗方法.
科学领域:
- 药理学 药理学是指药理学的学科.
- 血液学 血液学 血液学
- 临床医学 临床医学
背景情况:
- 抗血小板药物对于动脉疾病至关重要,但会增加出血风险.
- 在接受抗血小板治疗的患者中,诸如脑内出血等疾病的死亡率较高.
- 逆转剂的目的是减轻出血,但具有血栓形成的风险.
研究的目的:
- 审查目前用于逆转抗血小板药物效应的策略.
- 强调需要基于证据的逆转药物的疗效.
- 评估现有和新出现的逆转选择的风险和好处.
主要方法:
- 对抗血小板逆转药物的临床试验和研究的审查.
- 对结局的分析,包括死亡率,发病率和血栓性并发症.
- 评估诸如血小板输血,特兰胺酸,德斯莫普列辛和本特拉西马布等药物.
主要成果:
- 血小板输血显示脑内出血的风险增加.
- 在服用抗血小板药物或不服用抗血小板药物的患者中,特兰胺酸的风险/益处似乎相似.
- 德斯莫普列辛显示出有希望的结果,但需要进一步研究;本特拉西马布在单臂试验中显示出有效性.
结论:
- 对抗血小板逆转策略的高质量研究有显著的未满足需求.
- 临床相关的结果必须指导逆转剂疗效的评估.
- 将逆转效益与血栓形成风险之间的平衡仍然是一个关键的挑战.
相关概念视频
Desensitization and Tachyphylaxis
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
Several...
Several...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Formation of the Platelet Plug
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Drug toxicity: Drug–Drug Interaction
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...


